SITC 2020 Exhibitors

10x Genomics was founded on the vision that this century will bring unprecedented advances in biomedicine and transform the way we understand and treat disease. We build solutions to interrogate biological systems at a resolution and scale that matches the complexity of biology. Our rapidly expanding suite of products, which includes instruments, consumables, and software, have enabled our customers to make innovative and fundamental discoveries across multiple research areas, including cancer, immunology, and neuroscience.
Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. Our goal is to develop and commercialize immune-driven diagnostics and therapeutics tailored to each individual patient.
Advanced Cell Diagnostics, Inc. is a leader in the emerging field of molecular pathology, developing cell and tissue-based diagnostic tests for personalized medicine. ACD’s products and services are based on its proprietary RNAscopeTM Technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity. ACD technology is used in proprietary diagnostic tests for cancer management and validates biomarkers for targeted therapeutic development.
Akoya Biosciences, The Spatial Biology Company™, offers comprehensive solutions for multiplexed immunofluorescence for biomarker discovery and clinical research. The CODEX® System is the only benchtop platform that offers ultrahigh plex imaging of whole tissues at single-cell resolution, including FFPE samples. The Phenoptics™ Platform is the only multiplex IHC solution with the robustness and high throughput for translational research and clinical trials.
Alkermes plc is a fully integrated, global biopharmaceutical company focused on developing innovative medicines for the treatment of serious, chronic central nervous system (CNS) diseases, with an emerging oncology program. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit and follow us on Twitter @AstraZenecaUS.
Axion Biosystems
Berkeley Lights is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell- based products for our customers. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell- based product value chain.
Biognosys is dedicated to advancing innovative mass spectrometry-based tools that provide functional insights into the proteome. To accelerate drug discovery and development, we work globally alongside more than 250 pharma and biotech companies. Our aim is to provide novel insights, as well as actionable biological answers, through our unique technological and analytical abilities.
BioIVT, formerly BioreclamationIVT, is a leading provider of control and disease state samples including tissues, immune cells and biofluids from both normal donors and oncology cohorts. Combining technical expertise, exceptional customer service, and unparalleled access to biospecimens, BioIVT partners with scientists in ELEVATING SCIENCE.
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients’ lives through science.
Leading provider of immune monitoring, genomics, histopathology, and biomarker development services to the biopharmaceutical industry with laboratory facilities located globally. Leveraging its integrated platforms, Caprion-HistoGeneX supports the entire drug development cycle, from discovery to clinical trials. The company operates globally with laboratories located in Canada, USA, Belgium, UK, Australia, and China.
We are the only independent community-based cancer clinic fully dedicated to Phase I clinical trials. We specialize in immunotherapy for solid tumors. Our agile model makes for efficient and rapid accrual. CBOI also incubates Biocytics (application of living cells) and offers CDMO services in our ISO-7 cleanrooms, beta-testing of medical devices, and other cell therapy related development.
CDI Laboratories, Inc. (CDI) has assembled the most complete suite of technologies available for the discovery of antibody-based biomarkers. CDI employes these proprietary technologies to discover novel ways to study immune response, diagnose cancer and anticipate checkpoint blockade side-ef¬fects. CDI markets these technologies as brands: Antygen™ — High-throughput immune biomarker profiling of patient antibody repertoires via protein microarray & proteome-wide phage display. Monomabs™ — Highly-validated monoclonal antibodies for pathology; proven monospecific versus >21,000 human proteins.
Celetrix next-generation electroporation technology provides the highest-efficiency and lowest toxicity electroporation for all cells including immune cells, stem cells, neurons and all cell lines. Celetrix supports clinical research in CAR-T and gene editing.
Cellular Technology, Ltd. (CTL: is the leading provider of automated ImmunoSpot and BioSpot analyzers for cell based assays (EliSpot, FluoroSpot, Target Cell Visualization/killing assay (TVA), Virus neutralization, Plaque reduction). CTL also provides EliSpot assay kits (T cell and B cell EliSpot/FluoroSpot) , TVA kits, Serum- free Culture Medium , Cryopreservation Medium and large libraries of cryo-preserved Human PBMCs. In addition, CTL has a CLIA-certified CRO division which provides immune monitoring services.
ClearLight Biotechnologies
Clinigen is devoted to making sure that healthcare professionals can access the right medicine for their patients anywhere around the globe. At Clinigen US, we are focused on facilitating better health through life-changing therapeutics. To learn more about our commitment to immunotherapy for appropriate patients, visit Full Prescribing Information including Black Box Warning can be found at
Covance is a business segment of LabCorp, a leading global life sciences company, which provides contract research services to the drug, medical device and diagnostics, crop protection and chemical industries. Employing over 21,000 people worldwide, we are the world’s most comprehensive CRO, dedicated to improving health and improving lives.
Crown Bioscience is a cutting edge technology company providing drug discovery and services in cardiovascular and metabolic disease, oncology, and inflammation. We provide preclinical immunotherapy research platforms to support the successful transition of immunotherapeutics from the lab into the clinic including models for the evaluation of CAR-T cell therapies, syngeneics, and humanized models.
Description: The Daicel Group, known for decades of leadership in Pharma and Biopharma applications with world-class purification solutions for antibodies, chiral pharmaceuticals and genomic DNA, is proud to feature Actranza lab. at SITC. Actranza lab. is the latest breakthrough in the delivery of nucleic acids, including genes, oligonucleotides and genetic vaccines, into living cells using Daicel's proprietary/patented pyro-drive jet injector technology. Contact us today to find out more about how Actranza lab. can help Deliver a breakthrough in your vaccine research!
Immuno-oncology is a top priority for Merck KGaA, Darmstadt, Germany, and Pfizer Inc. Their global strategic alliance enables the companies to benefit from each other's strengths/capabilities and explore the potential of the anti-PD-L1 avelumab. The alliance jointly develops/commercializes avelumab, and is investigating it as a mono- or combination therapy to treat cancer.
Exelixis is a commercially successful, oncology-focused biotechnology company that strives to accelerate discovery, development and commercialization of new medicines for difficult-to-treat cancers. Discovery efforts have resulted in four approved products, partnering with leading pharmaceutical companies to bring these important medicines to patients worldwide. We are committed to prudently reinvesting in our business to maximize our pipeline potential, all to deliver the next generation of Exelixis medicines and help cancer patients recover stronger and live longer.
Exelixis is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers.
For more than 40 years, we've been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions.
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics. The has a broad clinical and pre-clinical product pipeline. Our differentiated pipeline stands as proof of our ability to identify and address the areas of unmet treatment need and includes three Genmab-created antibodies, out-licensed and developed by partners, that were approved by the U.S. Food and Drug Administration with breakthrough designations—Daratumumab, Ofatumumab and Teprotumumab
HalioDx is an immuno-oncology diagnostic company with CLIA certified laboratories in Marseille, France and Richmond, Virginia. Our expertise allows the company to provide first-in-class immune-based diagnostic solutions to health care professionals but also execute biomarkers studies and companion diagnostic assay developed in conformity with regulations and in partnership with pharmaceuticals industries.
With Immudex' proprietary Dextramer® and dCODE Dextramer® technologies, we develop and market research reagents and assay solutions, enabling researchers to measure disease-specific immunity. All products are ensure the highest standards, resulting in reproducible monitoring. GMP grade and diagnostic Dextramer reagents are available and currently in use within the USA and Europe. Under an agreement with US Cancer Immunotherapy Consortium and European Cancer Immunotherapy Consortium, Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide.
Incyte Corporation Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company's web site at Follow @Incyte on Twitter at
IONpath, Inc., provides high-definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate discovery and improve human health. IONpath’s MIBI™ (multiplexed ion beam imaging) platform breaks through the limitations of traditional immunohistochemistry, enabling a deeper understanding of the tissue microenvironment with highly multiplexed, quantitative single-cell analysis. With MIBI technology and its expert pathology and data science teams, IONpath provides actionable insights for translational/clinical researchers in immuno-oncology, immunology, neuroscience, and infectious disease at leading biopharma/academic organizations.
iRepertoire offers a wide array of flexible and affordable options for next-generation sequencing of the immune repertoire. Service options include single-cell sequencing of V(D)J-C pairing of BCRs and TCRs (iPair and iPair+); multi-chain analyses (RepSeq and RepSeq+), and all services come with complimentary basic bioinformatics. Additional options are available, in terms of products, for all-inclusive reagent kits and automated library preparation platforms. Let us help you find the right tool for you immune research.
At Kite, our singular focus is on cell therapy — the use of genetically modified immune cells programmed to target tumors — which we believe has the potential to change the way cancer is treated. Through our focused efforts and industry and academic partnerships we have been able to advance our industry-leading pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates with the goal of treating hematological cancers and solid tumors.
Lunaphore is a Swiss company developing next generation tissue autostainers. Its innovative microfluidic tissue processor has demonstrated to dramatically reduce assay time in multiplexed in situ stainings and aims to bring -omics like approaches to tissue diagnostics. Lunaphore’s products are only commercially available in Europe.
This Virtual Reality Room invites learners to experience a virtual world illustrating the role of immune checkpoint inhibition and its interaction with tumors demonstrating PD-L1 expression, deficient mismatch repair (dMMR) and microsatellite instability (MSI)-high status. The virtual reality animations will also allow learners to explore the potential immunotherapy-related adverse events of colitis and pneumonitis from an intimate perspective.
For more than a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Today, Merck continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases around the world.
MS Bioworks is a proteomics service provider. We offer multiple workflows that can move your immuno-oncology work forwards. We offer complete immunopeptidomics workflows from cell culture and peptide enrichment to LC-MS/MS and peptide identification. We also offer tumor protein profiling services with the option for incorporating proteogenomics workflows. Whether you are interested in PK or PD applications of the immunopeptidome we can help.
NanoString® is a leading provider of life science tools for translational research and diagnostics. Cited in over 3,200 peer-reviewed publications, the nCounter® Analysis System measures gene and protein expression to profile novel biomarkers. The company's GeoMx™ Digital Spatial Profiler enables highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. For more information, please visit
Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera's tumor-informed assay is optimized to detect low levels of ctDNA, with high accuracy in identifying MRD and recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers.
NeoGenomics is an industry-leading cancer diagnostics and pharma services company. We enable advanced oncology care leveraging the most extensive solid tumor and hematological test menus, sub-specialized pathology, and expertise in biomarker development. We partner closely with our pharma clients to meet program objectives and delivery from discovery through CDx commercialization.
Nilogen Oncosystems offers cancer drug development services for pharmaceutical and biotechnology companies. We perform correlative studies between ex vivo drug responses and multiple aspects of the tumor microenvironment to develop companion diagnostics that can be applied to clinical trials and patient care in our CLIA certified lab. Our proprietary drug testing platforms utilize fresh patient tumor tissue with intact tumor immune microenvironment to accurately assess the therapeutic potential of drug treatments.
As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally, and we are finding innovative ways to expand access to our latest treatments.
OracleBio is a global leader in quantitative digital pathology, providing image analysis services to Pharma and Biotech clients worldwide. Leveraging multiple software platforms, the company delivers robust data packages within a quality management framework to support clinical trials and translational research. As image analysis experts, OracleBio specialises in cellular phenotyping of multiplex stained tissue and has built a strong reputation as the go-to company for complex image analysis.
Personalis is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue or blood sample.
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of patients. Today, Pfizer Oncology has an industry-leading portfolio of 22 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, prostate, kidney and lung cancers, as well as leukemia and melanoma.
Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We support translational immunology researchers with innovative technologies and service through our Thermo Scientific, Applied Biosystems, Invitrogen, Gibco and Ion Torrent brands.
Visiopharm® is a world leader in AI-driven precision pathology software operating with over 750 licenses in more than 40 countries. Visiopharm’s software supports scientists, pathologists, and image analysis experts in academic institutions, biopharmaceutical industry, and diagnostic centers. Our AI-based image analysis supports research and drug development research, while CE-IVD APPs support primary diagnostics. With the most advanced and sophisticated artificial intelligence and deep learning, Visiopharm delivers tissue data mining tools, precision results, and workflows.
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. WuXi AppTec's open-access platform is enabling more than 4,000 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated."